Cellectis (CLLS) EBITDA Margin (QoQ) (2015 - 2026)
Cellectis (CLLS) EBITDA Margin (QoQ) (2015 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | Cellectis | 281.48 Mn | 95.81 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -29,918.00 |
| Dec 31, 2025 | -15,932.00 |
| Sep 30, 2025 | 8,018.00 |
| Jun 30, 2025 | 7,576.00 |
| Mar 31, 2025 | -4,908.00 |
| Dec 31, 2024 | -1,751.00 |
| Sep 30, 2024 | 14,703.00 |
| Jun 30, 2024 | 24,793.00 |
| Mar 31, 2024 | 999,050.00 |
| Dec 31, 2023 | 288,419.00 |
| Sep 30, 2023 | -6,590.00 |
| Jun 30, 2023 | 358,661.00 |
| Mar 31, 2023 | -1.68 Mn |
| Dec 31, 2022 | 1.56 Mn |
| Sep 30, 2022 | -1.35 Mn |
| Jun 30, 2022 | -33,431.00 |
| Mar 31, 2022 | -151,611.00 |
| Dec 31, 2021 | 27,039.00 |
| Sep 30, 2021 | -17,435.00 |
| Jun 30, 2021 | -25,761.00 |